Abstract
Purpose
The significance of aggressive chemotherapy for stage IV gastric carcinoma was retrospectively examined.
Methods
This study analyzed 94 stage IV gastric cancer patients who underwent surgery with or without subsequent chemotherapeutic treatment. There were 29 potentially curative patients classified as Curability B and 65 noncurative patients classified as Curability C. These patients were divided into three groups chronologically according to the primary type of drugs administered as the 1st (1989–1998), the 2nd (1999–2002), and the 3rd term (2003–2005).
Results
There was no significant difference in the survival time among the three groups (n = 94). The survival time of the patients classified as Curability C (n = 65) in the 3rd-term group (n = 17) was longer than that of the other two groups (P < 0.05). Similarly, the survival time in patients who were given new drugs and regimens (n = 22) was longer than that in those who were not (n = 43) in Curability C (P < 0.05). A multivariate analysis proved that the administrations of new drugs and regimens were independent factors for the prolongation of survival times for patients undergoing noncurative surgery (P < 0.01).
Conclusions
These findings suggested that the administration of new anticancer drugs might bring about a favorable outcome for stage IV gastric cancer patients, especially in those with evidence of a residual tumor.
Similar content being viewed by others
Reference
Nishiyama M. Chemotherapy for gastric cancer in Japan. Int J Clin Oncol 2008;13:191–192.
Yagi Y, Seshimo A, Kameoka S. Prognostic factors in stage IV gastric cancer: univariate and multivariate analyses. Gastric Cancer 2000;3:71–80.
Yoshida Y, Yamaguchi K, Osada S, Kawaguchi Y, Takahashi T, Sakashita F, et al. Challenge for a better combination with basic evidence. Int J Clin Oncol 2008;13:212–219.
Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003;6:2–8.
Emi Y, Yamamoto M, Takahashi I, Orita H, Kakeji Y, Kohnoe S, et al. Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer. Surg Today 2008;38:1013–1020.
Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer. Review article. Gastric Cancer 2009;12:132–141.
Cutsem E, Haller D, Ohtsu A. The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer 2002;5suppl 1:17–22.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English ed. Gastric Cancer 1998;1:10–24.
Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al. Randomized controlled trial of adjuvant uraciltegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468–1476.
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2008;357:1810–1820.
Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of 5-fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. J Br Cancer 1995;71:587–591.
Boku N. Chemotherapy for metastatic disease: Review from JCOG trials. Int J Clin Oncol 2008;13:196–200.
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215–221.
Nashimoto A, Yabusaki H, Nakagawa S, Takii Y, Tsuchiya Y, Tanaka O. Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer. Anticancer Res 2009;29:4689–4696.
Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today 2010;40:295–300.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okuyama, T., Korenaga, D., Koushi, K. et al. The prognostic significance of chemotherapy for stage IV gastric cancer patients: A single-institution experience. Surg Today 41, 935–940 (2011). https://doi.org/10.1007/s00595-010-4403-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-010-4403-0